Zhejiang Hisoar Pharmaceutical Co., Ltd. Stock price

Equities

002099

CNE000001PY2

Pharmaceuticals

End-of-day quote Shenzhen S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
5.56 CNY +0.36% Intraday chart for Zhejiang Hisoar Pharmaceutical Co., Ltd. -6.24% -22.67%
Sales 2021 2.48B 344M Sales 2022 2.7B 374M Capitalization 11.35B 1.57B
Net income 2021 95M 13.15M Net income 2022 88M 12.18M EV / Sales 2021 4.87 x
Net cash position 2021 1.24B 172M Net cash position 2022 489M 67.71M EV / Sales 2022 4.02 x
P/E ratio 2021
137 x
P/E ratio 2022
140 x
Employees 2,788
Yield 2021
1.21%
Yield 2022
0.71%
Free-Float 51.53%
More Fundamentals * Assessed data
Dynamic Chart
Zhejiang Hisoar Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 300 million worth of its shares. CI
Hisoar Pharma Chairman Plans Up to 20 Million Yuan Investment MT
Zhejiang Hisoar Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Zhejiang Hisoar Pharma Passes Good Manufacturing Practice Compliance Inspection MT
Zhejiang Hisoar Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Zhejiang Hisoar Pharma Registers New Drug For Diabetes Patients MT
Zhejiang Hisoar Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Elects Tao Hong as Non-Independent Director; and Yu Yongping, Qian Jianmin and Liang Chao as Independent Directors CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Hainan Visum Pharmaceutical Co Ltd announced that it has received $15 million in funding from Zhejiang Hisoar Pharmaceutical Co., Ltd. CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Zhejiang Hisoar Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
More news
1 day+0.36%
1 week-6.24%
Current month+0.18%
1 month+1.28%
3 months-19.88%
6 months-35.35%
Current year-22.67%
More quotes
1 week
5.49
Extreme 5.49
5.89
1 month
5.40
Extreme 5.4
6.04
Current year
3.91
Extreme 3.91
7.33
1 year
3.91
Extreme 3.91
10.11
3 years
3.91
Extreme 3.91
11.93
5 years
3.91
Extreme 3.91
11.93
10 years
2.96
Extreme 2.955
18.60
More quotes
Managers TitleAgeSince
Chief Executive Officer 47 99-12-31
Director of Finance/CFO 42 19-11-12
Director/Board Member 51 99-07-31
Members of the board TitleAgeSince
Director/Board Member 58 07-06-30
Chief Executive Officer 47 99-12-31
Director of Finance/CFO 42 19-11-12
More insiders
Date Price Change Volume
24-03-28 5.56 +0.36% 7,222,300
24-03-27 5.54 -1.25% 8,011,301
24-03-26 5.61 -1.41% 6,837,064
24-03-25 5.69 -2.74% 6,423,208
24-03-22 5.85 -1.35% 8,957,939

End-of-day quote Shenzhen S.E., March 27, 2024

More quotes
ZHEJIANG HISOAR PHARMACEUTICAL CO.,LTD. is a China-based company principally engaged in the manufacture and sale of pharmaceutical materials and dyes. The Company operates through two segments: Pharmaceutical segment and Dye segment. Pharmaceutical segment manufactures and sells Active Pharmaceutical Ingredients (APIs) and preparations, as well as provides customized production and supporting research and development services for international pharmaceutical companies. The Company's pharmaceutical products comprise antibiotic series, hypoglycemic series and cardiovascular series. Dye segment is mainly involved in the manufacture and sale of environmentally friendly reactive dyes, dye intermediates and pigment intermediates. The Company distributes its products within domestic market and to overseas markets.
More about the company

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Zhejiang Hisoar Pharmaceutical Co., Ltd. - Shenzhen S.E.